Brookdale Senior Living Appoints Margaret Cabell as Chief Sales Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Brookdale Senior Living announced that Margaret Cabell has been named Chief Sales Officer effective June 15, 2026. "As Chief Sales Officer, Margaret's leadership will be instrumental in advancing our sales strategy and improving alignment throughout the organization," said Nick Stengle, Brookdale's CEO. Most recently, she served as Chief Community Relations Officer and Head of Sales at A Place for Mom.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BKD
Wall Street analysts forecast BKD stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.620
Low
13.00
Averages
13.33
High
14.00
Current: 13.620
Low
13.00
Averages
13.33
High
14.00
About BKD
Brookdale Senior Living Inc. is a premier operator of senior living communities, operating and managing 584 communities in 41 states. The Company operates independent living, assisted living, memory care, and continuing care retirement communities. It operates through three segments: Independent Living; Assisted Living and Memory Care; and Continuing Care Retirement Communities (CCRCs). Its Independent Living segment includes owned or leased communities that are primarily designed for middle to upper-income seniors who desire to live in a residential setting that feels like home, without the efforts of ownership. Its Assisted Living and Memory Care segment includes owned or leased communities that offer housing and 24-hour assistance with activities of daily living for the Company's residents. The CCRCs segment includes large owned or leased communities that offer a variety of living arrangements and services to accommodate a broad spectrum of physical ability and healthcare needs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Ratings Overview
- Morgan Stanley Bullish on Onto Innovation: Morgan Stanley initiates Onto Innovation with an overweight rating, citing potential upside to consensus estimates driven by its process control capabilities in both front-end and back-end operations, suggesting a favorable re-rating ahead.
- Needham Initiates Ceva as Buy: Needham launches coverage of Ceva with a Buy rating and a price target of $55, indicating a 70x P/E based on CY27 EPS estimates, as the company is positioned to benefit from AI advancements in the semiconductor sector.
- UBS Initiates Jade Biosciences as Buy: UBS rates Jade Biosciences as a Buy, highlighting its best-in-class potential, with expectations that the FDA's acceptance of shorter eGFR kidney function data will expedite enrollment in pivotal studies.
- Morgan Stanley Upgrades Ferrari: Morgan Stanley upgrades Ferrari to overweight from equal weight, raising the price target to $438, arguing that the current de-rating overstates brand risk and that the company’s wealth creation and product pipeline support a positive re-rating.
See More
Brookdale Senior Living Reports May 2026 Occupancy Rates
- Occupancy Observations: Brookdale Senior Living has released its occupancy data for May 2026, reflecting the company's operational status in the senior care market; while specific figures are not disclosed, this information is crucial for investors assessing company performance.
- Market Dynamics: As the elderly population increases, fluctuations in Brookdale's occupancy rates could significantly impact future revenue expectations, especially in an increasingly competitive market environment.
- Financial Impact: Changes in occupancy rates are directly linked to the company's revenue streams, making it essential for investors to monitor this metric to evaluate the company's financial health and its position within the industry.
- Strategic Significance: The occupancy data will provide a basis for Brookdale's future strategic decisions, particularly in expanding services and optimizing operational efficiency.
See More
Brookdale Senior Living Reports May 2026 Occupancy Rates
- Occupancy Rate Increase: In May 2026, Brookdale's weighted average occupancy rose by 250 basis points year-over-year to 82.5%, indicating the company's sustained appeal and recovery in customer demand within the senior living market.
- Same Community Performance: The weighted average occupancy for same communities reached 82.9%, improving by 130 basis points year-over-year, demonstrating Brookdale's effective strategies in maintaining its existing customer base while attracting new clients.
- Seasonal Trends: Historically, Brookdale experiences strong occupancy growth from May to September each year, and this data aligns with past trends, suggesting potential business growth in the upcoming months.
- Community Coverage: As of May 2026, Brookdale operates 543 communities across 41 states, serving approximately 46,000 residents, showcasing its extensive footprint and market leadership in the senior living services sector.
See More
Brookdale Senior Living Shares Hit Oversold Territory
- Oversold Signal: Brookdale Senior Living Inc (Ticker: BKD) saw its RSI drop to 28.5 during Tuesday's trading, indicating an oversold condition with shares hitting a low of $11.895, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 75.6, BKD's 28.5 RSI reflects relative weakness in its stock price, potentially attracting investors looking for undervalued stocks, which could drive future rebounds.
- Historical Performance: BKD's 52-week low stands at $6.37 per share, while the high is $17.09, with the current trading price at $12.05, indicating potential upside within its trading range that may interest short-term traders.
- Investor Sentiment: Despite the current oversold condition, investors should cautiously assess market sentiment and fundamentals to avoid risks that may arise during a rebound, ensuring the rationality of their investment decisions.
See More
Wall Street's Stock Analysis Highlights
- Sell Recommendation for Shutterstock: Shutterstock (SSTK) faces a projected 13.7% sales decline over the next 12 months, with average customer spending down by 87.9%, indicating a challenging demand environment; its earnings per share have fallen by 6.3% annually over the last three years, despite revenue growth, highlighting significantly lower profitability of incremental sales.
- Brookdale's Performance Issues: Brookdale (BKD) has seen flat sales over the past five years, with a projected 4.4% sales drop in the next 12 months; a high net-debt-to-EBITDA ratio of 11x could force the company to raise capital under unfavorable terms if market conditions worsen, with its current stock price at $12.98 and an EV/EBITDA ratio of 15.8.
- Buy Recommendation for Eli Lilly: Eli Lilly (LLY) has achieved an impressive 41.8% annual revenue growth over the past two years, reflecting significant market share gains, while adjusted operating profits and efficiency have improved, and share repurchases have amplified shareholder returns with a 29.6% growth in earnings per share, trading at $990.36 per share with a forward P/E of 26.1.
- Market Sentiment Analysis: While Wall Street's bullish forecasts for several stocks may be overly optimistic, Eli Lilly's strong fundamentals and growth potential position it as a worthy investment, reflecting the market's focus on high-quality companies.
See More
Brookdale's Q1 Results Fall Short of Expectations
- Revenue Miss: Brookdale reported Q1 revenue of $764.9 million, falling short of analyst expectations of $771.2 million, reflecting a 6% year-on-year decline that highlights challenges faced during the ongoing restructuring, potentially impacting future market confidence.
- Adjusted EPS Beat: The adjusted EPS came in at -$0.02, beating analyst estimates of -$0.09, indicating that despite the overall revenue decline, the company has made some progress in cost control, which may lay the groundwork for future profitability.
- Significant Operating Margin Improvement: The operating margin increased from 3.9% in the same quarter last year to 8.1%, reflecting gradually improving operational efficiency during the restructuring process, which could provide investor confidence and signal future profit potential.
- Negative Market Reaction: Despite management's optimistic outlook for the future, the stock price dropped from $14.18 to $12.98, indicating market concerns regarding the company's restructuring and operational challenges, which may influence investor decisions.
See More
Latest Wall Street Ratings Overview
- Morgan Stanley Bullish on Onto Innovation: Morgan Stanley initiates Onto Innovation with an overweight rating, citing potential upside to consensus estimates driven by its process control capabilities in both front-end and back-end operations, suggesting a favorable re-rating ahead.
- Needham Initiates Ceva as Buy: Needham launches coverage of Ceva with a Buy rating and a price target of $55, indicating a 70x P/E based on CY27 EPS estimates, as the company is positioned to benefit from AI advancements in the semiconductor sector.
- UBS Initiates Jade Biosciences as Buy: UBS rates Jade Biosciences as a Buy, highlighting its best-in-class potential, with expectations that the FDA's acceptance of shorter eGFR kidney function data will expedite enrollment in pivotal studies.
- Morgan Stanley Upgrades Ferrari: Morgan Stanley upgrades Ferrari to overweight from equal weight, raising the price target to $438, arguing that the current de-rating overstates brand risk and that the company’s wealth creation and product pipeline support a positive re-rating.
See More
Brookdale Senior Living Reports May 2026 Occupancy Rates
- Occupancy Observations: Brookdale Senior Living has released its occupancy data for May 2026, reflecting the company's operational status in the senior care market; while specific figures are not disclosed, this information is crucial for investors assessing company performance.
- Market Dynamics: As the elderly population increases, fluctuations in Brookdale's occupancy rates could significantly impact future revenue expectations, especially in an increasingly competitive market environment.
- Financial Impact: Changes in occupancy rates are directly linked to the company's revenue streams, making it essential for investors to monitor this metric to evaluate the company's financial health and its position within the industry.
- Strategic Significance: The occupancy data will provide a basis for Brookdale's future strategic decisions, particularly in expanding services and optimizing operational efficiency.
See More
Brookdale Senior Living Reports May 2026 Occupancy Rates
- Occupancy Rate Increase: In May 2026, Brookdale's weighted average occupancy rose by 250 basis points year-over-year to 82.5%, indicating the company's sustained appeal and recovery in customer demand within the senior living market.
- Same Community Performance: The weighted average occupancy for same communities reached 82.9%, improving by 130 basis points year-over-year, demonstrating Brookdale's effective strategies in maintaining its existing customer base while attracting new clients.
- Seasonal Trends: Historically, Brookdale experiences strong occupancy growth from May to September each year, and this data aligns with past trends, suggesting potential business growth in the upcoming months.
- Community Coverage: As of May 2026, Brookdale operates 543 communities across 41 states, serving approximately 46,000 residents, showcasing its extensive footprint and market leadership in the senior living services sector.
See More
Brookdale Senior Living Shares Hit Oversold Territory
- Oversold Signal: Brookdale Senior Living Inc (Ticker: BKD) saw its RSI drop to 28.5 during Tuesday's trading, indicating an oversold condition with shares hitting a low of $11.895, suggesting that recent heavy selling may be nearing exhaustion, prompting bullish investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 75.6, BKD's 28.5 RSI reflects relative weakness in its stock price, potentially attracting investors looking for undervalued stocks, which could drive future rebounds.
- Historical Performance: BKD's 52-week low stands at $6.37 per share, while the high is $17.09, with the current trading price at $12.05, indicating potential upside within its trading range that may interest short-term traders.
- Investor Sentiment: Despite the current oversold condition, investors should cautiously assess market sentiment and fundamentals to avoid risks that may arise during a rebound, ensuring the rationality of their investment decisions.
See More
Wall Street's Stock Analysis Highlights
- Sell Recommendation for Shutterstock: Shutterstock (SSTK) faces a projected 13.7% sales decline over the next 12 months, with average customer spending down by 87.9%, indicating a challenging demand environment; its earnings per share have fallen by 6.3% annually over the last three years, despite revenue growth, highlighting significantly lower profitability of incremental sales.
- Brookdale's Performance Issues: Brookdale (BKD) has seen flat sales over the past five years, with a projected 4.4% sales drop in the next 12 months; a high net-debt-to-EBITDA ratio of 11x could force the company to raise capital under unfavorable terms if market conditions worsen, with its current stock price at $12.98 and an EV/EBITDA ratio of 15.8.
- Buy Recommendation for Eli Lilly: Eli Lilly (LLY) has achieved an impressive 41.8% annual revenue growth over the past two years, reflecting significant market share gains, while adjusted operating profits and efficiency have improved, and share repurchases have amplified shareholder returns with a 29.6% growth in earnings per share, trading at $990.36 per share with a forward P/E of 26.1.
- Market Sentiment Analysis: While Wall Street's bullish forecasts for several stocks may be overly optimistic, Eli Lilly's strong fundamentals and growth potential position it as a worthy investment, reflecting the market's focus on high-quality companies.
See More
Brookdale's Q1 Results Fall Short of Expectations
- Revenue Miss: Brookdale reported Q1 revenue of $764.9 million, falling short of analyst expectations of $771.2 million, reflecting a 6% year-on-year decline that highlights challenges faced during the ongoing restructuring, potentially impacting future market confidence.
- Adjusted EPS Beat: The adjusted EPS came in at -$0.02, beating analyst estimates of -$0.09, indicating that despite the overall revenue decline, the company has made some progress in cost control, which may lay the groundwork for future profitability.
- Significant Operating Margin Improvement: The operating margin increased from 3.9% in the same quarter last year to 8.1%, reflecting gradually improving operational efficiency during the restructuring process, which could provide investor confidence and signal future profit potential.
- Negative Market Reaction: Despite management's optimistic outlook for the future, the stock price dropped from $14.18 to $12.98, indicating market concerns regarding the company's restructuring and operational challenges, which may influence investor decisions.
See More
